Company Description
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States.
Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia.
The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.
Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
| Country | United States |
| Founded | 1995 |
| IPO Date | Nov 5, 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Brendan O’Grady |
Contact Details
Address: 100 South Saunders Road, Suite 300 Lake Forest, Illinois 60045 United States | |
| Phone | 224 419 7106 |
| Website | assertiotx.com |
Stock Details
| Ticker Symbol | ASRT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001005201 |
| CUSIP Number | 04546C205 |
| ISIN Number | US04546C2052 |
| Employer ID | 94-3229046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brendan P. O'Grady | Chief Executive Officer and Director |
| Ajay Patel | Executive Vice President and Chief Financial Officer |
| Paul Schwichtenberg | Executive Vice President and Chief Transformation Officer |
| Bill Iskos | Senior Vice President of Operations |
| Molly Dir | Senior Vice President of Human Resources and Administration |
| Sam Schlessinger | Executive Vice President and General Counsel |
| Dr. Howard J. Franklin M.B.A., M.D. | Senior Vice President of Medical |
| Mary Pietryga | Executive Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2021 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 18, 2020 | 15-12B | Securities registration termination |
| May 22, 2020 | 8-K | Current Report |
| May 19, 2020 | 25-NSE | Filing |
| May 18, 2020 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 11, 2020 | 10-Q | Quarterly Report |
| May 11, 2020 | 8-K | Current Report |
| May 11, 2020 | 425 | Filing |
| Apr 24, 2020 | 8-K | Current Report |
| Apr 21, 2020 | 8-K | Current Report |